Single User License
INR 129080
Site License
INR 258160
Corporate User License
INR 387240

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Malignant Glioma-Pipeline Review, H2 2015

Malignant Glioma-Pipeline Review, H2 2015


  • Products Id :- GMDHC6872IDB
  • |
  • Pages: 116
  • |
  • July 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Malignant Glioma-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Malignant Glioma-Pipeline Review, H2 2015', provides an overview of the Malignant Glioma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Malignant Glioma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Malignant Glioma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Malignant Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Malignant Glioma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Malignant Glioma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Malignant Glioma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Malignant Glioma Overview 10

Therapeutics Development 11

Pipeline Products for Malignant Glioma-Overview 11

Pipeline Products for Malignant Glioma-Comparative Analysis 12

Malignant Glioma-Therapeutics under Development by Companies 13

Malignant Glioma-Therapeutics under Investigation by Universities/Institutes 15

Malignant Glioma-Pipeline Products Glance 16

Clinical Stage Products 16

Early Stage Products 17

Malignant Glioma-Products under Development by Companies 18

Malignant Glioma-Products under Investigation by Universities/Institutes 19

Malignant Glioma-Companies Involved in Therapeutics Development 20

Advantagene, Inc. 20

Amgen Inc. 21

AstraZeneca Plc 22

BBB Therapeutics B.V. 23

Eisai Co., Ltd. 24

Eli Lilly and Company 25

Genmab A/S 26

Lipopharma Therapeutics SL 27

MediGene AG 28

Nuo Therapeutics, Inc. 29

Pfizer Inc. 30

Stemline Therapeutics, Inc. 31

Tiziana Life Sciences Plc 32

Vicus Therapeutics, LLC 33

ZIOPHARM Oncology, Inc. 34

Malignant Glioma-Therapeutics Assessment 35

Assessment by Monotherapy Products 35

Assessment by Combination Products 36

Assessment by Target 37

Assessment by Mechanism of Action 39

Assessment by Route of Administration 41

Assessment by Molecule Type 43

Drug Profiles 45

(etodolac + propranolol hydrochloride)-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

2B3-101-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Ad-RTS-IL-12-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

ALD-451-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Carboxyamidotriazole Orotate-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Cell therapy for Malignant Glioma-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Cell Therapy for Refractory Gliomas-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Cell Therapy to Target EGFR for Malignant Glioma-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Cell Therapy to Target IL-13 for Malignant Glioma-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Dendritic Cell Therapy for Malignant Gliomas-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Dendritic Cell Therapy for Oncology-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Dendritic Cell Therapy for Oncology-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Dendritic Cell Therapy for Oncology-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Dendritic Cell Therapy for Recurrent Malignant Glioma-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

disufenton sodium-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

DNX-2401-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

G-207-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

galunisertib-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

GliAtak-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

IDD-004-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

irofulven-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

LD-224-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

marizomib-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

milciclib-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

Minerval-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

Monoclonal Antibody Conjugated to Antagonize EGFR for Brain Tumor and Glioblastoma Multiforme-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

rilotumumab-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

SL-701-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

Small Molecule for Brain Cancer and Malignant Glioma-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

temsirolimus-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

Vaccine to Target Wilm's Tumor 1 for Oncology-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

Malignant Glioma-Recent Pipeline Updates 97

Malignant Glioma-Dormant Projects 108

Malignant Glioma-Discontinued Products 111

Malignant Glioma-Product Development Milestones 112

Featured News & Press Releases 112

Jul 24, 2015: ZIOPHARM Announces Orphan Drug Designation for Ad-RTS-hIL-12 in the Treatment of Malignant Glioma 112

Apr 07, 2015: Key patent for Minerval in oncology granted in the United States by the USPTO 112

Oct 07, 2014: FDA Grants Orphan Drug Designation To DNAtrix's DNX-2401 For The Treatment Of Malignant Glioma 113

Feb 24, 2014: DNAtrix Awarded $10.8 Million Grant by the Cancer Prevention and Research Institute of Texas 113

Nov 19, 2012: Aeterna Zentaris Announces Positive Data From Phase I Trial Of Perifosine Combined With Temsirolimus In Malignant Glioma 114

Appendix 115

Methodology 115

Coverage 115

Secondary Research 115

Primary Research 115

Expert Panel Validation 115

Contact Us 115

Disclaimer 116

List of Tables

Number of Products under Development for Malignant Glioma, H2 2015 11

Number of Products under Development for Malignant Glioma-Comparative Analysis, H2 2015 12

Number of Products under Development by Companies, H2 2015 14

Number of Products under Investigation by Universities/Institutes, H2 2015 15

Comparative Analysis by Clinical Stage Development, H2 2015 16

Comparative Analysis by Early Stage Development, H2 2015 17

Products under Development by Companies, H2 2015 18

Products under Investigation by Universities/Institutes, H2 2015 19

Malignant Glioma-Pipeline by Advantagene, Inc., H2 2015 20

Malignant Glioma-Pipeline by Amgen Inc., H2 2015 21

Malignant Glioma-Pipeline by AstraZeneca Plc, H2 2015 22

Malignant Glioma-Pipeline by BBB Therapeutics B.V., H2 2015 23

Malignant Glioma-Pipeline by Eisai Co., Ltd., H2 2015 24

Malignant Glioma-Pipeline by Eli Lilly and Company, H2 2015 25

Malignant Glioma-Pipeline by Genmab A/S, H2 2015 26

Malignant Glioma-Pipeline by Lipopharma Therapeutics SL, H2 2015 27

Malignant Glioma-Pipeline by MediGene AG, H2 2015 28

Malignant Glioma-Pipeline by Nuo Therapeutics, Inc., H2 2015 29

Malignant Glioma-Pipeline by Pfizer Inc., H2 2015 30

Malignant Glioma-Pipeline by Stemline Therapeutics, Inc., H2 2015 31

Malignant Glioma-Pipeline by Tiziana Life Sciences Plc, H2 2015 32

Malignant Glioma-Pipeline by Vicus Therapeutics, LLC, H2 2015 33

Malignant Glioma-Pipeline by ZIOPHARM Oncology, Inc., H2 2015 34

Assessment by Monotherapy Products, H2 2015 35

Assessment by Combination Products, H2 2015 36

Number of Products by Stage and Target, H2 2015 38

Number of Products by Stage and Mechanism of Action, H2 2015 40

Number of Products by Stage and Route of Administration, H2 2015 42

Number of Products by Stage and Molecule Type, H2 2015 44

Malignant Glioma Therapeutics-Recent Pipeline Updates, H2 2015 97

Malignant Glioma-Dormant Projects, H2 2015 108

Malignant Glioma-Dormant Projects (Contd..1), H2 2015 109

Malignant Glioma-Dormant Projects (Contd..2), H2 2015 110

Malignant Glioma-Discontinued Products, H2 2015 111

List of Figures

Number of Products under Development for Malignant Glioma, H2 2015 11

Number of Products under Development for Malignant Glioma-Comparative Analysis, H2 2015 12

Number of Products under Development by Companies, H2 2015 13

Number of Products under Investigation by Universities/Institutes, H2 2015 15

Comparative Analysis by Clinical Stage Development, H2 2015 16

Comparative Analysis by Early Stage Products, H2 2015 17

Assessment by Monotherapy Products, H2 2015 35

Number of Products by Top 10 Targets, H2 2015 37

Number of Products by Stage and Top 10 Targets, H2 2015 37

Number of Products by Top 10 Mechanism of Actions, H2 2015 39

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 39

Number of Products by Top 10 Routes of Administration, H2 2015 41

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 41

Number of Products by Top 10 Molecule Types, H2 2015 43

Number of Products by Stage and Top 10 Molecule Types, H2 2015 43

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Advantagene, Inc.

Amgen Inc.

AstraZeneca Plc

BBB Therapeutics B.V.

Eisai Co., Ltd.

Eli Lilly and Company

Genmab A/S

Lipopharma Therapeutics SL

MediGene AG

Nuo Therapeutics, Inc.

Pfizer Inc.

Stemline Therapeutics, Inc.

Tiziana Life Sciences Plc

Vicus Therapeutics, LLC

ZIOPHARM Oncology, Inc.

Malignant Glioma Therapeutic Products under Development, Key Players in Malignant Glioma Therapeutics, Malignant Glioma Pipeline Overview, Malignant Glioma Pipeline, Malignant Glioma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com